Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Ripasudil in Patients with Fuchs Endothelial Corneal Dystrophy Undergoing Femtosecond Laser Assisted Cataract Surgery

Next Previous
X
Search
Trial Profile

The Effects of Ripasudil in Patients with Fuchs Endothelial Corneal Dystrophy Undergoing Femtosecond Laser Assisted Cataract Surgery

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ripasudil (Primary)
  • Indications Fuchs' endothelial dystrophy
  • Focus Therapeutic Use

    • Most Recent Events

    • 29 Jan 2025 Trial design changed from single blind to double blind. Assessment duration for primary endpoint has been changed.
    • 29 Jan 2025 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
    • 29 Jan 2025 Planned initiation date changed from 1 Oct 2023 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top